Member Info for Catchingpigeons

BoonCo ur spot on mate , look it wasn’t a great presentation we all agree on that, but DP did say some positive things re the Vaccine programme and he also emphasised the main focus of 4d right now is on the 0518 tie up with keytruda the worlds best selling drug … and he distinctly said that he was hopeful that the results in the NSCLC trial were going to be very similar to those acquired in the RCC trial where the primary endpoint was met early , and if it did then that would be a huge inflection point on a number of fronts
Lest we forget this is a company with numerous collaborations on the go not just with the likes of Merckx, & Pfizer but MD Anderson cancer centre ,the Imperial College , the MJ Fox foundation so for me the idea that Oxford finance are seriously considering foreclosing on a 5 million dollar advance when a milestone payment could drop at any point is beyond my comprehension tbh but maybe that’s just my confirmation bias kicking in , I get that , but i still believe there’s more chance of this suspension being good news than bad , but that’s just my take on it as always GLA

If ur invested here like me and u have a decent holding with the share price at 15-16p , a market cap of only 28 million , and the possibility of an immediate buyout / collaboration , or whatever being no more than slim at this juncture , then the big Q right now whether we agree with it or not , is to decide as to whether we do want to only allow the company to issue just 40% of the share capital , which will raise peanuts as SR points out …or 100% of the share capital which would at least give us half a chance bearing in mind ideally ,we somehow need to raise 45 million by the end of the year .
So As disappointed as I am at present ,I still believe in the science & I’m also convinced DP &JD think likewise , along with the company pipeline , products & people.
I’m also pretty convinced that once the Agm & the key resolutions are passed (assuming they are) ….that news flow will resume soon after ,as the company & us shareholders both desperately need it much higher than the current -hit show.
The other issue of course is that they can not surely want to be raising placing funds at these bat **** crazy levels .
This I’m sure is another reason why DP mentioned yesterday as to why the $150 million option they filed in the US earlier this year as I recall was done so in anticipation of raising cash but clearly at a much much higher price than it is today grrrrrr .
Anyway GLA

Another interesting article about Merckx looking at acquiring Seagen for a potentially a pretty large outlay

https://www.fiercepharma.com/pharma/merck-eyes-28b-purchase-seagen-amid-quest-diversify-star-cancer-drug-keytruda-wsj
More relevant to us however are these pieces in the article which implies to me at least that 4d have to be on the radar if we continue to build on the results we have had so far .
“For Merck, it’s under investor pressure to diversify from the forever growing Keytruda, which contributed 35%, or $17.2 billion, to Merck’s total sales in 2021.
The company did make some smaller purchases and one relatively large acquisition last year, shelling out $11.5 billion to take in Acceleron Pharma.
Recently, at the ongoing BIO 2022, Merck’s Jannie Oosthuizen, head of U.S. Human Health, told Fierce Biotech that the company is looking at deals where it can “add significant value to the system.”

“It really does continue to be broad, focused cutting-edge science that is innovative, that will produce value, and that will really help to build out the pipeline for the future,” Oosthuizen said.

(Sound familiar ? )

“A lot of it has been done in oncology. Clearly, that's where we focused a lot over the last few years. We continue to do that.”
In the meantime, I just hope we get some guidance tomoz that’s actually meaningful . GLA & come on 4d

Some great work here on the Q&As so hats off to all contributors & thanks for ur input fellas
Just read this article about top performing pharma companies in the U S for 2021 and both Pfizer and Merckx right up there in the top 5 . There is also a glowing summary on the merits & huge revenue generating beast that their keytruda drug has become for Merckx & I hadn’t realised that their coffers had been boosted by a $ 9 billion dollar cash windfall from the “Organon” separation last year.
To think they had revenue in 2021 of $47 billion dollars and yet they’re still here with 4d …3 years down the line …so surely that must say something give us all real hope that one of these days something will come to fruition very soon . Can but hope GLA
https://www.fiercepharma.com/special-reports/top-10-most-profitable-pharma-companies-2021

I reckon we need Taunton boy to start buying in again if he’s still with us ,and any other members of the Somerset massive .
I added yesterday but typically got my timing wrong yet again doh ! …altho 30p is still a crazy price imho .
Finally I see the April presentation for anticipated milestones remains unchanged so from next week we are only a couple of weeks from the end of Q2 .
Furthermore , John Doyle the CFO will have been in situ 6months so I’d like to think he’s earned his corn over that period & something will be announced anytime soon on the financing Q .

ANTICIPATED MILESTONES AND OBJECTIVES FOR 2022
Q2 2022

• First patient dosing in Phase II study of MRx0518 & Bavencio® in urothelial carcinoma
• Complete enrollment of Phase I study of MRx0518 in pancreatic cancer
• Present data from Part A of Phase I/II study of MRx-4DP0004 in Asthma at ATS conference (May 2022)

2H 2022

• Commence Part B of Phase I/II trial of MRx-4DP0004 in Asthma
• Commence Phase I trial of MRx0005 and MRx0029 in people with Parkinson’s disease
• Provide update and guidance on Blautix® in patients with irritable bowel syndrome (IBS)
• Provide update on next steps for MRx0518 & Keytruda® combination in Renal Cell Carcinoma (RCC)

Top post that MHB ,as u rightly say first and foremost unlocking that door to the Oxford finance would be huge step forward here & the 1 in 10 target based on what we know already must be a pretty decent possibility & with future funding worries averted this should see a major re rate pretty soon after.
As frustrating as the shareprice is for most Long term holders at the minute , the reality is , if the right news drops here, which it might at any time , it may just catch a lot of people out big time . Time will tell as always .Come on 4d . GLA

Morning porky I’m as keen as u are in hoping we get an update on something very soon but I’m not sure it’s going to be anything on Blautix just yet , as in the April presentation it’s scheduled for H2 so I’d be surprised if it came any earlier myself , but plenty of other things bubbling away that could materialise hopefully .

ANTICIPATED MILESTONES AND OBJECTIVES FOR 2022
Q2 2022
• First patient dosing in Phase II study of MRx0518 & Bavencio® in urothelial carcinoma
• Complete enrollment of Phase I study of MRx0518 in pancreatic cancer
• Present data from Part A of Phase I/II study of MRx-4DP0004 in Asthma at ATS conference (May 2022)

2H 2022
• Commence Part B of Phase I/II trial of MRx-4DP0004 in Asthma
• Commence Phase I trial of MRx0005 and MRx0029 in people with Parkinson’s disease
• Provide update and guidance on Blautix® in patients with irritable bowel syndrome (IBS)
• Provide update on next steps for MRx0518 & Keytruda® combination in Renal Cell Carcinoma (RCC)

At the time of the vaccine collaboration with MSD back in Oct 19 Daria Hazuda, Chief Scientific Officer of MSD said this
“A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health.
By applying 4D's MicroRx® technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines."

So 3 years on they’ve seen a pretty much clean bill of health for both safety & tolerability on every aspect of the 4D MicroRx platform & not only that but some very significant inroads in meeting some pretty impressive endpoints too on virtually all areas 4d has targeted to date & more specifically in cohorts with one of their own best selling drugs Keytruda

Under the terms of the agreement with MSD , 4D's proprietary MicroRx® platform will be paired with their own expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications.
4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration.
In addition to an upfront cash payment,
for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration.
( so $347.5 per indication x 3 so up to $1.044,000 in total )
Additionally , if any of that happens MSD will cover all the costs to take any of them to commercial endpoint .
In the last financial statement Axel said this (and I’m pretty sure that this was ratified by Duncan in one of this years interviews where he stated that good results had continued on the vaccine collaboration into 2022)

“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines.
This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.
In 2021 we continued to make good progress in this collaboration.

A quick resume then ..so bearing in mind the progress & results 4d have delivered over the 3 year period with LBPs coupled with the fact that this is precisely the kind of emerging new areas of science the MSD CSO is looking for … then I think it’s fair to say there is a pretty decent chance of MSD either taking us out completely or investing further but time will tell as always
Point being I think this will happen but that’s just my take on it and I’m defo no expert , I’m not an adviser I’m just invested here LT so Dyor & make ur own decisions . GLA

Afternoon all , just to pick up on Sangis point regarding the cash position .. look I fully accept it’s a realistic stance by people to question the financial position of the company ,
but it’s also reasonable to look a bit deeper into the detail for the purposes of balance & looking back further on the last financial update …am I missing something here as …the chairman says this

“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines. This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.

In 2021 we continued to make good progress in this collaboration.

Point being, we may be pretty close to one of these given we are into our 4th year of collaboration with MSD , they’re still here & tbf we’ve recently published some pretty half decent results and big money is very likely if that happens .

In the Financial outlook statement it then says this
“As of 31 December 2021, our cash and cash equivalents were £15.5 million.

After the year end, but before the signing of these financial statements, the Group received research and development tax credits of £3.2 million on its UK entities. “

So I’m reading that as we had £18.7 million and not £15.5 million at the time the update was published

He then says this .

“Excluding possible income from warrants, we believe that this additional cash …
the Spanish loan facility, (1million i believe )
along with existing cash and cash equivalents

…but before restrictive covenants on the Oxford loan ….

are sufficient to fund our projected operating requirements until the fourth quarter of 2022. “

(Which are the current guidelines and remain unchanged)

(So the Board feel they do have sufficient cash even with the restrictive covenant is my understanding of that .)

The Directors are continuing to explore sources of finance that are available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts.

The usual caveats are then applied , so yes a placing is a distinct possibility …but so are a raft of other things that could happen .

Fwiw I think the latter is far more likely myself & it is maybe wishful thinking, but after the recent updates I just can’t believe that someone like Merck is not going to step in at some point very soon and if so we won’t be at 33p
Not an advisor , defo no expert , so make ur own calls but any thoughts welcome GLA

Top post fella , well said that man !

Look I realise most people invested here will know this so I’m not trying to tell folk how to suck eggs ,but a golden rule in this game invariably is that u should never sell ur shares when it’s NT to buy on the ask …as the chances are the MM s are probably looking to fill an order , and once they have ur shares , the price will more often than not ,move up , meaning u get the bullseye classic quote of “look at what u could have won “
It’s been a long time coming this rise but in fairness I was of the view that the last few rns’ have been pretty bullish on the prospects for nuvec with the therapeutic angle , and like Leister said just recently we can’t be far off an update & if it’s half decent ,we may just be ready to start the car again at these crazy levels , so fingers crossed .GLA
just checked now I can still sell any shares at 3.23 up from 3.22 and yet I can only buy a max 1500 at 3.299 b4 it goes NT . Just popped higher now there’s a surprise

A decent buy just gone thru at 3.31

Defo something afoot here atm as just like yesterday despite any small selling pressure the bid has been lifted just like it has now where a 60k sale has prompted the mms to increase the price upwards and change the spread from 2.9-3.20 to 3-3.30 which suggests to me they know something we don’t or someone is buying despite the volumes not being that significant as yet . Either way I’m not complaining GLA

Firstly I accept it’s a totally realistic stance by people to question the financial position of the company ..perfectly reasonable
but it’s also reasonable to look a bit deeper into the detail for the purposes of balance and further on in todays report …the chairman says this

“We continue to advance our ground-breaking collaboration with MSD in the field of vaccines. This collaboration, which is associated with potential milestone payments totaling over $1 billion across up to three undisclosed indications, utilizes MicroRx® to discover and develop Live Biotherapeutics for vaccines.

In 2021 we continued to make good progress in this collaboration.

Point being, we may be pretty close to one of these given we are into our 4th year of collaboration with MSD , they’re still here and we’ve just had some pretty stunning results and big money is very likely if that happens .
In the Financial outlook statement it then says this
“As of 31 December 2021, our cash and cash equivalents were £15.5 million.
After the year end, but before the signing of these financial statements, the Group received research and development tax credits of £3.2 million on its UK entities. “

(We didn’t know that )
“Excluding possible income from warrants, we believe that this additional cash …the Spanish loan facility, along with existing cash and cash equivalents but before restrictive covenants on the Oxford loan are sufficient to fund our projected operating requirements until the fourth quarter of 2022. “

(Which are the current guidelines and remain unchanged)

The Directors are continuing to explore sources of finance that are available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts.

The usual caveats are then applied , so yes a placing is a possibility …but so are a raft of other things that could happen .
I think the latter is far more likely myself & it is maybe wishful thinking, but after the recent updates I just can’t believe that someone like Merck is not going to step in at some point very soon .
Cos If they did , then this won’t be at 42p that I do know. GLA

Like all things with Hzm it’s taken us a while ,but fair play to them , this is a monumental achievement so just sit back if ur loaded up , get the cigar out and just wait .
At these levels this has to right up there as the best value play on aim imho. Anyway GLA .

This might be one of the first done today based on Katie’s tweet https://twitter.com/katie_proactive/status/1507277293017878529?s=21
Just a reminder that anybody shorting is only looking to shaft the personal investor , that’s you reading this right now .. don’t let them rid u of ur golden tickets unless u see it otherwise of course but just remember with a partner like Merckx worth close to 200 billion dollars and 8 billion in cash based on the last set of accounts that I could find , so anything could happen here after that last Rns involving a drug they are heavily involved with and 4d valued at just £100 million . !!!
Dyor as always but for me it’s a total no brainer as this was 180 don’t forget with us no where near where we are today at 52 p .

That Rns today is just reward for all those people actually who believed in the science as that’s as probably as good at it gets for reenforcing ur faith in what 4d pharma is really all about and it’s absolutely massive potential on a global scale GLA

Morning all , been invested here since prob 2017 I love Hzm btw & it’s a monster in the making for sure I’ve always said and believed that, but tbf Reggie imho is not going to be far off with his prediction as I’ve always believed that jezzer & the BOD had initially set their sights on 2023 as the optimum time for this project to finally cash in it’s chips, as he’s always thought that by then ,commodity prices would be at optimum level , what with the EV revolution and change to a greener economy really taking shape by then . The massive hike in the price of nickel reenforces that view and I have no problem with that having been here so long anyway . The rainy season in para state is primarily Nov/Dec to AprMay so being realistic as to how much can be done this year b4 year end , it’s a pretty fair bet b4 it is actually producing that it could be a little while off in truth . The reality is however that as we all know many things could happen progressively value wise with this investment as we move along the journey and that’s why I’ve always stuck it out as the most important aspect for me was Hzm securing that humongous finance package of over £600 million ffs . Just incredible .So it’s just sit back and wait as it will happen but I can tell u now I take any timescale promise that jezzer hands out with a huge block of salt as I can’t ever recollect him hitting one , but if ur here for the big one & can see it thru ur going does that matter as if u can u are going to be seriously well rewarded . Anyway enough from me GL to all invested here exciting times ahead .

There aren’t many other posters like sang on this Bb who actually provides the quality and quantity of research he does …an example of which , is that one today … hands up who else knew about that appointment ?
I know I didn’t ….and the same with his reasons to invest here summary which is not only relevant but useful for new and long term holders alike
I readily admit I will miss his input and his insight big time if he does opt not to post again as there’s no one else like him imho
The idea he’s a two Bob trader is a total fallacy too as no body of that ilk would know as much as he does and let’s be honest here , we’ve all been exasperated with the state of play with 4d at some point, especially whilst watching the drip drip decline in the shareprice over the past 12 months …& he’s no different i suspect ,so yes he probably had reduced his holding , as we all probably have at some point ,knowing full well the share price would fall .
At 25/26p if u believe in the science and /or u have the means of course , u would buy back in or just buy more just like he says he has, and who wouldn’t ?
As for his detractors what I don’t understand is , If I felt like a few others on here and I was genuinely upset or irked by his manner or anything else , I’d just filter him so I just can’t fathom why folk still have a problem as that’s what the filter option is for , so use it if it’s not what u want to read .
Anyway , I hope u reconsider ur decision Sang to post again as I’ve gained a lot from ur insight but if not , then thanks for sharing what u have , as it’s been much appreciated .
come on 4d let’s be having u and GL to all invested here

Irrespective of the truly awful geopolitical situation and human tragedy in ukraine this is the starker side of it as commodities are still in huge demand and look here the Chinese are quick to capitalise as ever
https://www.bloomberg.com/news/articles/2022-03-02/china-moves-to-secure-commodity-supplies-rocked-by-ukraine-war